Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Sinopharm Group Co ( (HK:1099) ) is now available.
Sinopharm Group Co. Ltd. has announced the composition of its board of directors, detailing the roles and functions of each member. The announcement outlines the structure of five board committees, highlighting the leadership and membership roles of the directors, which may impact the company’s governance and strategic direction.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. operates in the healthcare industry, primarily focusing on the distribution of pharmaceutical and healthcare products. The company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance and is involved in various aspects of the healthcare supply chain.
YTD Price Performance: -12.30%
Average Trading Volume: 7,885,508
Technical Sentiment Signal: Sell
Current Market Cap: HK$58.26B
For a thorough assessment of 1099 stock, go to TipRanks’ Stock Analysis page.